Epoetin theta, sold under the brand name Biopoin among others, is a copy of the human hormone erythropoietin.[1][2]
Clinical data | |
---|---|
Trade names | Biopoin, Eporatio |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
PubChem SID | |
DrugBank | |
Chemical and physical data | |
Formula | C815H1317N233O241S5 |
Molar mass | 18396.19 g·mol−1 |
The most common side effects include shunt thrombosis (clots that can form in blood vessels of patients on dialysis, a blood clearance technique), headache, hypertension (high blood pressure), hypertensive crisis (sudden, dangerously high blood pressure), skin reactions, arthralgia (joint pain) and influenza (flu)-like illness.[1]Epoetin theta was approved for medical use in the European Union in October 2009.[1] It is on the World Health Organization's List of Essential Medicines.[3]
Medical uses
editEpoetin theta is indicated for the treatment of symptomatic anemia in adults.[1]
References
edit- ^ a b c d e "Biopoin EPAR". European Medicines Agency (EMA). 16 December 2009. Retrieved 26 January 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ a b "Eporatio EPAR". European Medicines Agency (EMA). 16 December 2009. Retrieved 26 January 2021. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
attribution contains material copied from Biopoin | European Medicines Agency https://www.ema.europa.eu/en/medicines/human/EPAR/biopoin 2021
External links
edit- "Epoetin theta". Drug Information Portal. U.S. National Library of Medicine.